Global Recombinant Protein Drug Report offers market size, share, overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors/traders, factors affecting market, forecast and other important information for key insight.

The business intelligence summary of Recombinant Protein Drug market is a compilation of the key trends leading the business growth related to the competitive terrain and geographical landscape. Additionally, the study covers the restraints that upset the market growth and throws light on the opportunities and drivers that are anticipated to foster business expansion in existing and untapped markets. Moreover, the report encompasses the impact of the COVID-19 pandemic, to impart a better understanding of this industry vertical to all the investors.

Request a sample Report of Recombinant Protein Drug Market at:https://www.marketstudyreport.com/request-a-sample/2894297?utm_source=algosonline.com&utm_medium=TS

Key highlights from COVID-19 impact analysis:

Other highlights from the Recombinant Protein Drug market report:

Ask for Discount on Recombinant Protein Drug Market Report at:https://www.marketstudyreport.com/check-for-discount/2894297?utm_source=algosonline.com&utm_medium=TS

A gist of the regional landscape:

Table of Contents:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-recombinant-protein-drug-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Related Reports:

2. Global Diabetes Test Strips Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-diabetes-test-strips-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Read More Reports On: https://www.marketwatch.com/press-release/flexible-packaging-market-size-growing-at-47-cagr-to-hit-usd-3354-billion-by-2025-2020-09-03?tesla=y

Read More Reports On: https://www.marketwatch.com/press-release/progressing-cavity-pump-market-2020-company-profiles-trends-by-types-and-application-operating-business-segments-2025-2020-09-04?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See original here:
Growth Factors of Recombinant Protein Drug Market with Emerging Trends and Revenue Estimation By 2025 - AlgosOnline

Recommendation and review posted by Bethany Smith

September 05, 2020

According to the U.S. Department of Labors website, Sept. 2, 2019 is the 125th anniversary of Labor Day being celebrated as a national holiday.

The DOL website offers a brief history: The first Labor Day holiday was celebrated on Tuesday, Sept. 5, 1882, in New York City, in accordance with the plans of the Central Labor Union. The Central Labor Union held its second Labor Day holiday just a year later, on Sept. 5, 1883. By 1894, 23 states had adopted the holiday, and on June 28, 1894, President Grover Cleveland signed a law making the first Monday in September of each year a national holiday.

Presently, workforce has become one of the leading drivers for location choices. In an article from the Wharton University of Pennsylvania The Headquarters Checklist: How Do Companies Pick A Location, Wharton management professor Peter Cappelli, Director of the Schools Center for Human Resources states: For most businesses, the issue of location choice now is driven by labor: Will we be able to attract the white-collar skills we need? For unskilled or semi-skilled jobs, will we be able to get it at a price we want to pay? No business goes to the Silicon Valley or New York City because it is cheap; they go because of the labor supply. Christopher Thornberg, founding partner of Los Angeles economics research firm Beacon Economics, further strengthens this thought, It boils down to access to clients, access to labor force, access to suppliers these all play a role in these decisions.

Just as it was important to start the celebration of the workforce in 1882, the importance of the available workforce in site selection has made it even more vital and worthy of continued celebration.

The Maysville-Mason County Area Chamber of Commerce believes that Workforce is the heart of everything we do. It begins with our Mission Statement: To enhance economic growth, promote development and provide leadership of the business community in the Maysville-Mason County Area. That may still sound rather general, but thats the beauty of it the Chamber can move in almost any area where our membership has a need. To simplify it, we can break it down to three words, Enhance, Promote and Lead. But my favorite way to describe the Chamber is that we are a Connector. We can connect one person to another, or someone to the information or product that they need.

It has been a pleasure to provide the leadership for the process of becoming certified as a Kentucky Work Ready Community. We had the opportunity to prove that Mason County has the quality workforce employers are looking for. Our workforce has graduated from high school, has some college experience to a two-year or higher degree, and has attained Career Readiness Certificates. The Chamber, in conjunction with the Mason County School System, has developed the Work Ethic Seal Program to reward Mason County Juniors and Seniors for exhibiting the habits employers look for in an employee. One of the best outcomes of the program has been connecting all the stakeholders needed for the process: Economic Development, Business and Industry, Elected Officials, Education, Workforce Development and those who work with the Veteran, Disabled, Ex-offender, and Medicaid Populations. It takes all of us working together!

Always looking to the future, we partner with (enhance) and actively serve on committees for the Kentucky Career Center, Business Services Team and Maysville Community and Technical College. We produce (promote) a Relocation Guide to use when talking with new businesses or to help a new resident navigate settling in the area. We also produce the Maysville/Mason County map to help us all find our way around. We were a founding sponsor of the Maysville Young Professionals Network and continue to support them as they provide a connection to our new, younger residents. We regularly provide Professional Development opportunities (lead) such as our Exceeding Customer Expectations seminar on Sept. 26 and our Annual Leadership Conference. The Chamber helped to start the Leadership Horizons program which has continued for 20 years. We are proud to be a part of the steering committee to make Maysville the First Green Dot City and have had a couple of opportunities to represent Maysville at the State level.

Everything we do supports our workforce. It doesnt matter if the business is along the river or on top of the hill, or if they have one employee or 600, our goal is to connect them to the resources that are needed.

On this 126th Labor Day, lets all take a moment to thank each other for the great job everyone does. Truly, Big things are happening in Maysville and we have our workforce to thank for it.

Read the original here:
Painting the town red - Ledger Independent

Recommendation and review posted by Bethany Smith

Coronaviruses (CoV) are a group of viruses whose antigens are expressed on their membranes in a characteristic crown like appearance, hence giving them their name (from Latin corona [crown]). Since their initial discovery in 1965,1 about 46 species have been identified in animals and humans with 2 species, namely, severe acute respiratory syndrome (SARS)-CoV-1 and Middle Eastern Respiratory Syndrome (MERS)-CoV receiving a great deal of attention due to their high rate of transmission and mortality.2 In December 2019, a novel strain of CoV emerged in the city of Wuhan, China and was termed SARS-CoV-2 as it had an 80% genetic similarity with the SARS-CoV-1 virus.3 This new infection which was also named COVID-19, based on the year of its appearance, rapidly spread throughout the world and was announced as a global pandemic on 11 March 2020. The SARS-CoV-2 virus is an RNS virus that belongs to the -CoV subgroup and is characterized by having spike (S) proteins which facilitate viral cell entry, membrane (M) proteins and envelope (E) proteins which assist in viral assembly, and nucleocapsid (N) proteins which mediate viral transcription.4 The SARS-CoV-2 S protein undergo proteolytic priming by transmembrane protease, serine 2 (TMPRSS2) and gain access into host cells through the angiotensin-converting enzyme 2 (ACE2) receptor (Figure 1).5

Figure 1. Cellular entry mechanism

The ACE2 receptors are widely expressed in various tissues including the lungs, cardiovascular system, gastrointestinal system, nervous system, and the testes. The identification of ACE2 receptors in human testes forms the basis of a potential impact for the virus on the male reproductive system. After all, a number of viruses including the Ebola, Zika, herpes simplex, Epstein-Barr, human papilloma, and Mumps have been known to illicit orchitis or to undergo shedding within the seminal fluid. Other CoV, such as the SARS-CoV-1 have been also associated with orchitis.6 While there is a significant increase in the number of publications on COVID-19 infection since the emergence of the disease, the impact of SARS-CoV-2 infection on the male reproductive system and conception has been generally under-investigated. This was the main reason for our systematic review of published literature to understand the potential impact of SARS-CoV-2 infection on male reproduction.

We conducted a literature search using PubMed and Google Scholar as search engines and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The keyword strings included (severe acute respiratory syndromecoronavirus 2 OR severe acute respiratory syndrome coronavirus 2 OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV OR SARS CoV2 OR SARS CoV 2) AND (semen OR sperm* OR seminal OR testes OR testicular OR male fertil* OR male infertil* OR epididymis OR prostate OR testosterone OR LH OR FSH OR pregnancy OR ART OR assisted reproduc* OR IVF OR in vitro fertilization OR ICSI OR intracytoplasmic sperm injection OR cryopreservation). A total number of 1,171 articles were retrieved and after screening the titles, abstracts, and full texts, 24 articles were considered eligible for inclusion in this study. Six articles investigated the impact of SARS-CoV-2 infections on semen parameters.7-12 while 3 articles addressed male reproductive hormones13-15 and the remaining 15 articles assessed pregnancy outcomes.16-31

Semen samples from 120 patients with active or resolving infections were tested for the presence of SARS-CoV-2 viral RNA. Positive results were identified from 6 patients representing 5% of the tested samples. A single small-sampled study investigated the impact of SARS-CoV-2 infection on semen parameters and reported a significant reduction in sperm concentration, total number of sperm per ejaculate, total number of motile sperm, and total number of progressively motile sperm in patients with moderate infection in comparison to those with mild infection or normal controls.9

With regards to reproductive hormones, there is evidence stating that the androgenic state could be inversely correlated with the severity of COVID-19 infection. Ma et al. observed significantly higher luteinizing hormone (LH) levels and significantly lower testosterone: LH and follicle-stimulating hormone: LH ratios in recovered patients in comparison to healthy counterparts.13 Rastrelli et al. reported a negative association between total testosterone and CRP levels in COVID-19 recovered patients.14 Schroeder et al. observed that the majority of men with active infection had low testosterone and dihydrotestosterone levels.15

As for the effect of COVID-19 infection on pregnancy outcomes, 15 studies including 598 confirmed cases of SARS-CoV-2 assessed the effect of infection on women during their third trimester. While the virus had a minimal influence on maternal mortality (0.8%), intensive care unit admission was observed in 8.5% of women, and preterm delivery was seen in 33.2% of them. 30% of neonates required neonatal intensive care unit (NICU) admission and perinatal mortality was 1.5%. Vertical transmission was reported in 2.3% of cases. Four case-control studies were analyzed. Only Li et al. observed a slightly higher rate of maternal complications and preterm delivery in COVID-19 confirmed cases compared with normal controls.31 The remaining three studies did not report any significant differences.23, 27, 28

We then applied a strengths-weaknesses-opportunities-threats (SWOT) analysis of the available evidence on the topic. While SARS-CoV-2 may be associated with alterations in male and female reproduction, low quality of evidence is noted. Reasons for this finding include a less diligent peer-review process that is practiced on COVID-19 related research, the under-sized and observational designs of the available studies, and the lack of information on the consequences of infection during earlier stages of pregnancy. Taking this into consideration together with the fact that this pandemic will most likely persist for several years, efforts made to propose new standards to reproductive practices may be threatened by the low quality of evidence available so far.

We further elaborated on the current recommendations with regards to the practice of assisted reproduction during the COVID-19 pandemic (AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE (ASRM) PATIENT MANAGEMENT AND CLINICAL RECOMMENDATIONS DURING THE CORONAVIRUS (COVID-19) PANDEMIC)

In conclusion, the evidence regarding a putative impact of SARS-CoV-2 infection on male reproduction, as well as the potential of SARS-CoV-2 viral transmission through seminal fluids, remains inconclusive. Currently, extra precautions are strongly recommended for natural or ART-related conception, as clear evidence regarding the impact of the SARS-CoV-2 and the possible complications of COVID-19 on reproductive outcomes require additional investigation.

Written by:Ahmad Majzoub, MD1, 2, 3 and Ashok Agarwal, PhD3

Excerpt from:
Male Fertility and the COVID-19 Pandemic: Systematic Review of the Literature - Beyond the Abstract - UroToday

Recommendation and review posted by Bethany Smith

For a world crippled by the coronavirus, salvation hinges on a vaccine.

But in the United States, where at least 4.6 million people have been infected and nearly 155,000 have died, the promise of that vaccine is hampered by a vexing epidemic that long preceded COVID-19: obesity.

Scientists know that vaccines engineered to protect the public from influenza, hepatitis B, tetanus and rabies can be less effective in obese adults than in the general population, leaving them more vulnerable to infection and illness. There is little reason to believe, obesity researchers say, that COVID-19 vaccines will be any different.

Will we have a COVID vaccine next year tailored to the obese? No way, said Raz Shaikh, an associate professor of nutrition at the University of North Carolina-Chapel Hill.

Will it still work in the obese? Our prediction is no.

More than 107 million American adults are obese, and their ability to return safely to work, care for their families and resume daily life could be curtailed if the coronavirus vaccine delivers weak immunity for them.

In March, still early in the global pandemic, a little-noticed study from China found that heavier Chinese patients afflicted with COVID-19 were more likely to die than leaner ones, suggesting a perilous future awaited the U.S., whose population is among the heaviest in the world.

And then that future arrived.

As intensive care units in New York, New Jersey and elsewhere filled with patients, the federal Centers for Disease Control and Prevention warned that obese people with a body mass index of 40 or more known as morbid obesity or about 100 pounds overweight were among the groups at highest risk of becoming severely ill with COVID-19. About 9% of American adults are in that category.

As weeks passed and a clearer picture of who was being hospitalized came into focus, federal health officials expanded their warning to include people with a body mass index of 30 or more. That vastly expanded the ranks of those considered vulnerable to the most severe cases of infection, to 42.4% of American adults.

Obesity has long been known to be a significant risk factor for death from cardiovascular disease and cancer. But scientists in the emerging field of immunometabolism are finding obesity also interferes with the bodys immune response, putting obese people at greater risk of infection from pathogens such as influenza and the novel coronavirus. In the case of influenza, obesity has emerged as a factor making it more difficult to vaccinate adults against infection. The question is whether that will hold true for COVID-19.

A healthy immune system turns inflammation on and off as needed, calling on white blood cells and sending out proteins to fight infection. Vaccines harness that inflammatory response. But blood tests show that obese people and people with related metabolic risk factors such as high blood pressure and elevated blood sugar levels experience a state of chronic mild inflammation; the inflammation turns on and stays on.

Adipose tissue or fat in the belly, the liver and other organs is not inert; it contains specialized cells that send out molecules, like the hormone leptin, that scientists suspect induces this chronic state of inflammation. While the exact biological mechanisms are still being investigated, chronic inflammation seems to interfere with the immune response to vaccines, possibly subjecting obese people to preventable illnesses even after vaccination.

An effective vaccine fuels a controlled burn inside the body, searing into cellular memory a mock invasion that never truly happened.

Evidence that obese people have a blunted response to common vaccines was first observed in 1985 when obese hospital employees who received the hepatitis B vaccine showed a significant decline in protection 11 months later that was not observed in non-obese employees. The finding was replicated in a follow-up study that used longer needles to ensure the vaccine was injected into muscle and not fat.

Researchers found similar problems with the hepatitis A vaccine, and other studies have found significant declines in the antibody protection induced by tetanus and rabies vaccines in obese people.

Obesity is a serious global problem, and the suboptimal vaccine-induced immune responses observed in the obese population cannot be ignored, pleaded researchers from the Mayo Clinics Vaccine Research Group in a 2015 study published in the journal Vaccine.

Vaccines also are known to be less effective in older adults, which is why those 65 and older receive a supercharged annual influenza vaccine that contains far more flu virus antigens to help juice up their immune response.

By contrast, the diminished protection of the obese population both adults and children has been largely ignored.

Im not entirely sure why vaccine efficacy in this population hasnt been more well reported, said Catherine Andersen, an assistant professor of biology at Fairfield University who studies obesity and metabolic diseases. Its a missed opportunity for greater public health intervention.

In 2017, scientists at UNC-Chapel Hill provided a critical clue about the limitations of the influenza vaccine. In a paper published in the International Journal of Obesity, they showed for the first time that vaccinated obese adults were twice as likely as adults of a healthy weight to develop influenza or flu-like illness.

Curiously, they found that adults with obesity did produce a protective level of antibodies to the influenza vaccine, but they still responded poorly.

That was the mystery, said Chad Petit, an influenza virologist at the University of Alabama.

One hypothesis, Petit said, is that obesity may trigger a metabolic dysregulation of T cells, white blood cells critical to the immune response. Its not insurmountable, said Petit, who is researching COVID-19 in obese patients. We can design better vaccines that might overcome this discrepancy.

Historically, people with high BMIs often have been excluded from drug trials because they frequently have related chronic conditions that might mask the results. The clinical trials underway to test the safety and efficacy of a coronavirus vaccine do not have a BMI exclusion and will include people with obesity, said Larry Corey, MD, of the Fred Hutchinson Cancer Research Center, who is overseeing the phase 3 trials sponsored by the National Institutes of Health.

Although trial coordinators are not specifically focused on obesity as a potential complication, Corey said, participants BMI will be documented and results evaluated.

Timothy Garvey, MD, an endocrinologist and director of diabetes research at the University of Alabama, was among those who stressed that, despite the lingering questions, it is still safer for obese people to get vaccinated than not.

The influenza vaccine still works in patients with obesity, but just not as well, Garvey said. We still want them to get vaccinated.

This article was originally published on August 6, 2020, by Kaiser Health News. It is republished with permission.

Read the original post:
America's Obesity Epidemic Threatens Effectiveness of Any COVID Vaccine - POZ

Recommendation and review posted by Bethany Smith

The global Osteoporosis Treatment market study encloses the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). With bottom-up and top-down approaches, the report predicts the viewpoint of various domestic vendors in the whole market and offers the market size of the Osteoporosis Treatment market. The analysts of the report have performed in-depth primary and secondary research to analyze the key players and their market share. Further, different trusted sources were roped in to gather numbers, subdivisions, revenue and shares.

The research study encompasses fundamental points of the global Osteoporosis Treatment market, from future prospects to the competitive scenario, extensively. The DROT and Porters Five Forces analyses provides a deep explanation of the factors affecting the growth of Osteoporosis Treatment market. The Osteoporosis Treatment market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers. In addition, the macro- and microeconomic aspects are also included in the research.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2705363&source=atm

segment by Type, the product can be split intoBisphosphonatesParathyroid Hormone TherapyCalcitoninSelective Estrogen Inhibitors Modulator (SERM)Market segment by Application, split intoHospitalsClinicOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Osteoporosis Treatment status, future forecast, growth opportunity, key market and key players.To present the Osteoporosis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Osteoporosis Treatment are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Purchase reports at discounted prices!!! Offer valid till midnight!!!

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2705363&source=atm

The Osteoporosis Treatment market research covers an exhaustive analysis of the following data:

The Osteoporosis Treatment market research addresses critical questions, such as

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2705363&licType=S&source=atm

The global Osteoporosis Treatment market research considers region 1 (Country 1, country 2), region 2 (Country 1, country 2) and region 3 (Country 1, country 2) as the important segments. All the recent trends, such as changing consumers demand, ecological conservation, and regulatory standards across different regions are covered in the report.

Read this article:
Osteoporosis Treatment Market Estimated to Discern 2X Expansion by 2019-2025 - StartupNG

Recommendation and review posted by Bethany Smith

The global market for media, sera and reagents in biotechnology should reach $5.5 billion by 2023 from $4.1 billion in 2018 at a compound annual growth rate (CAGR) of 6.0% for the period 2018-2023.

Request For Report [emailprotected]https://www.trendsmarketresearch.com/report/sample/12029

Report Scope:

Cell culture products are used from the point of drug discovery through the process of drug development. Cell culture products are used mainly for research purposes, for production of biopharmaceuticals, and for educational purposes. This report focuses on the global market for media, sera and reagent products used in the cell culture industry and discusses the applications in various arenas of biomedical and life science research. The report addresses the whole market for cell culture including the research segment, production segment, contract segment, and others segment, which includes the in vitro diagnostics and educational sector.

The scope of the study is worldwide. Current market dynamics, market drivers, restraints, trends, regulatory issues, and strategic developments are discussed in the report. In the regional analysis, the report identifies and analyzes market size and forecasts for the U.S., Europe and emerging markets. The emerging markets for media, sera and reagents in biotechnology include India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand, and other countries.

Also included in the report are relevant patent analyses and comprehensive profiles of companies that lead the market for media, sera and reagents in the cell culture industry. A few prominent players in this industry are Thermo Fisher Scientific, Merck KGaA, GE Healthcare Life Sciences, BD Biosciences, and Corning Inc.

Report Includes:

An overview of the global markets and technologies for media, sera and reagents used in biotechnology. Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021. Information on different types of cell cultures and products from cell culture technology as well as the advantages and disadvantages for the use of various types of media. Detailed analysis of the cell culture industrys structure. Discussion covering the applications of cell culture technology with an emphasis on usage in the research, production, and contract segments. Profiles of major players in the media, sera, and reagents industry.

Report Summary

In the past decade, there has been a significant shift in the nature of the products being manufactured and sold by biotechnology companies. Innovative products are coming to market that help to increase the growth and differentiation of cells in in vitro conditions. Launch of innovative cell culture products and growing demand for biopharmaceuticals reflect increased use of cell culture products.

The global biopharmaceutical portfolio of today is a sign of increased therapeutic competition and expansion in a number of targeted therapies. These trends have given rise to highly specific manufacturing requirements, including cell culture media, sera and reagents. The fundamental shift in the pharmaceutical industry from small-molecule or chemical-based drugs towards biotherapeutics and a focus on consistently improving the efficiency and effectiveness of production are spurring an evolution in cell culture technology that is needed to support advanced biopharmaceutical manufacturing. Development of cell culture products, especially serum-free and animal-component-free media, has improved manufacturing processes by conferring many advantages.

Get Complete TOC with Tables and [emailprotected]https://www.trendsmarketresearch.com/report/discount/12029

The global market for cell culture products is driven by increased demand for biologics including biosimilars; by use of cell-based methods for vaccine production; and by use of cell lines for new drug developments. Ever-increasing demand for biopharmaceuticals has forced manufacturers to move toward contract manufacturing and research organizations, which will help the cell culture market to grow further during the forecast period of 2016 to 2021.

This report analyzes the market under three main segments: sera, media and reagents. All three categories are witnessing growth because of increased demand for biopharmaceuticals and research activities in the field of regenerative medicine. Use of mammalian cells to increase capacity, scalability and flexibility in vaccine production is an additional factor for the growth of the cell culture product market. Major companies operating in the cell culture market include BD Biosciences, Lonza Group, Sigma-Aldrich Corp. (a part of Merck KGaA), and Thermo Fisher Scientific Inc.

Innovation in biotechnology is interrelated with research and development (R&D) discoveries. As the biopharmaceutical portfolio continues to evolve, the manufacturing technologies and superior cell culture products offered by companies such as Sartorius Stedim Biotech SA, EMD Millipore (a part of Merck KGaA), and others will continue to advance in the coming years.

<<>>https://www.trendsmarketresearch.com/report/covid-19-analysis/12029

In 2015, the U.S. was the largest market for cell culture products, accounting for about 42.1% of the global market. The U.S. has one of the most supportive environments for the development and commercialization of new drugs, as it is the worlds largest free-pricing market for pharmaceuticals and has high per capita incomes. A large elderly population and high rates of chronic diseases and affordability are other factors that make the U.S. suitable for the development and consumption of drugs. Support from the government for medical research, an unparalleled scientific and research base, and an innovative biotechnology sector are the major factors that make the U.S. market the preferred home for growth in the healthcare industry, which also includes biotechnology.

Table of Contents

Chapter 1 IntroductionStudy Goals and ObjectivesReasons for Doing This StudyContributions of the Study and For WhomScope of ReportMethodologyInformation SourcesGeographic BreakdownAnalysts CredentialsRelated BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology BackgroundTerminologyHistorical Events in Cell Culture DevelopmentTypes of Cell CultureCell Line, Cell Strain and Transformed Cell LinesCell Culture ContaminationQuality-Control Considerations in Cell CultureBasic Requirements of Cell CulturesCell cultureCulture medium/MediaCell lineProkaryotesEukaryotesSubcultureOsmolalityZwitterionMonolayer sloughingSerumPhosphorylationMutagenesisCarcinogenesisTumorigenicityPrimary Cell CultureSecondary Cell CultureCharacteristics of Immortalized Cell LinesMorphology of Cells in CultureControl of Cell Culture ContaminationQuality of Reagents and Materials UsedPlace of origin and Integrity of Cell LinesAvoidance of Microbial ContaminationEnvironmental MonitoringCell culture MediaSerumCell Culture ReagentsChallenges of Primary Cell Isolation and CultureAdvantages and Disadvantages of Primary Cell CultureBasic Components of Cell Culture MediaBuffering SystemsPhenol RedInorganic SaltAmino AcidsCarbohydratesProteins and PeptidesFatty Acids and LipidsVitaminsTrace ElementsMedia SupplementsAntibioticsSerumTypes of Cell Culture Media for Animal Cell CultureNatural MediaArtificial MediaThe Four Types of Artificial MediaSerum-containing MediaSerum-free MediaProtein-free MediaChemically Defined MediaAdvantages of Using SerumRisks Associated with the Use of SerumBiological Response ModifiersCell Dissociation ReagentsOther ReagentsAntibioticsAmino AcidsOther Growth Supplements

Chapter 4 Regulatory AspectsBiological License ApplicationsBiologics Administrative ActionsRecallsOther Regulatory Issues

Chapter 5 New DevelopmentsNew Developments in Cell Culture Application

See the original post:
In-depth Research On Media, Sera And Reagents In Biotechnology Market Insights, And Forecast Till 2018-2023 - Scientect

Recommendation and review posted by Bethany Smith

This story is Parts 3 and 4 of a four-part series on the hemp industry in Colorado. Read and listen to Parts 1 and 2 here.

Colorados top three commodity crops are wheat, beans and corn. But theres a new kid on the block: hemp and its confusing sex life and relationship to marijuana is complicating matters.

Prohibition relegated cannabis to basements and garages where it would be grown in secret for decades. But as regulations loosened, hemp has moved to outdoor fields and industrial-size greenhouses.

Mike Workman owns New Earth Hemp Company out of Laporte, Colorado, and even he is humbled by this shift in scale.

Ser Williams / KUNC

Whatever you think you know, you dont know when youre trying to plant an acre of it, he said.

Outdoor growing is a lot cheaper than indoor growing, but it comes with its own set of challenges.

Then you have, you know, bugs, weather, hail, snow, said Ted Duerr, a hemp farmer, breeder, and co-owner of BDG Genetics in the small town of Frederick in southern Weld County. Pollen is one of the biggest things.

Plants produce pollen. So, how could that be an issue?

The unique reproductive life of hemp

This is where science and sex come into play. As a plant matures, it produces a flower. Males produce pollen, which pollinate female flowers, which in turn develop fruits also known as seeds.

Most plants contain male and female parts on the same plant, sometimes even in the same flower. But hemp is unique one plant will have only male flowers while another will have only female. And females can transform.

Female hemp plants are hermaphrodites, meaning they can turn into males. Depending on what youre growing hemp for -- fiber, seed oil or the chemical cannabinoids the unexpected sex-switch can be a problem.

Ser Williams / KUNC

If youre in it for the fiber, pollen doesnt affect your crop, so it doesnt matter what sex your plants are.

Ser Williams / KUNC

Ser Williams / KUNC

If youre growing hemp for seeds to press into oil, you want a female plant to be fertilized by a males pollen. As Ted Duerr explained, those strains need the males in there to pollinate and create the grain in the flower.

But to grow hemp for the flower or cannabinoids you need a virgin female flower that never comes into contact with pollen.

According to Workman, you can revert females into a masculine form, but you cant really revert males into a feminine form. This is a problem, because once a female plant turns into a male, it can fertilize other females in the field, and make the flowers develop seeds.

For CBD production, high CBD genetics, all these people that are going for smokable flowers, CBD oil, everything like that, you do not want males in your field, because you do not want seeds in your flower, said Duerr.

Since pollen travels on the wind, Duerr says a neighboring hemp crop with male plants could impact the outcome of your field. This happened last year.

A guy that we know did 600 acres of grain and fiber and there was multiple people around him that were trying to do smaller acreage for CBD oil and smokable flower, but needless to say, all their crops were ruined for what they wanted to do cause they all became seeded, he said.

Even with current genetic techniques, the biology underlying the sex switch is not well understood. It could be dependent on the environment.

Other important traits like THC concentration are dependent on the environment, too. But while a male plant wont make your crop illegal, too much THC will.

Ser Williams / KUNC

The deal with cannabinoids

Listen to part 4 of the audio here

THC is a psychoactive chemical compound in marijuana. Its what gets you high when its smoked or consumed. THC is just one cannabinoid, but the plant produces over 100 different cannabinoids like CBD and CBG that hemp growers are after for medicinal uses. CBG is produced first, and then specific enzymes convert CBG into either CBD or THC.

Ser Williams / KUNC

While cannabis was being grown indoors and in secret -- during prohibition the plant was grown for one purpose.

If it had not been for prohibition, cannabis and hemp would not be what they are today, and they would just probably be, itd be like, wed all be smoking hemp, wed all be smoking rope, said Workman.

Marijuana breeders continue to coax CBG into THC, thereby increasing THC content. According to the Drug Enforcement Agency, average THC concentration increased from 4% in the mid-90s to 12% today. THC can be found as high as 25% at some dispensaries.

But now, breeders need the plant to take the other fork in the road: the path that turns CBG into CBD.

For hemp growers, like Workman and Duerr, THC levels are strictly regulated and cannot exceed 0.3%.

It takes one day extra in the field for you to go from safe to hot. Thats problematic. Its basically a scenario that can turn innocent farmers into criminals, said Brett Eaton, owner of Green Cherry Organics, a hemp breeding company in Fort Collins.

Before a farmer harvests, the Colorado Department of Agriculture samples flowers from a hemp field to test for cannabinoid levels.

Thats the worst part of this job, said Brian Koontz, the hemp program manager with the Colorado Department of Agriculture. A lot of its very fun, but come September, October we start getting hot results back from the lab. When I say hot results that means its gone above the allowable three-tenths of one percent, he said. We demand by law that it be disposed of in a manner thats irretrievable and does not enter the stream of commerce and does not leave the registered land area.

Last year, 99 hemp fields in Colorado were above the limit. They were either burned or plowed into the soil on site.

Breeding the magic plant

Eaton and other hemp breeders are trying to find the perfect variety a female plant that would never transform into a male and never produce too much THC (while producing plenty of other cannabinoids).

Ser Williams / KUNC

Ser Williams / KUNC

Slowly over about three years of time, we had amassed about 286 phenos in house, and thats where we go on what we call the pheno-hunt, said Eaton.

The phenotype of a plant is how genes express themselves to display observable characteristics. While you cant see the chemicals in a plant, you can measure them, so high CBD is a desirable phenotype.

But its not just about the cannabinoid profile. You have to be able to grow the plant too.

We have an R&D department where we focus on growth trails first and foremost, Eaton said. Well do everything from rooting trials, soil density trials, soil nutrition trials, water trials

Once you cross the parent plants, you assess the offspring for the best combination of all of these traits. Like the differences between siblings, genetics from the same set of parents will produce an array of phenotypes.

For instance, Im going through a CBG genetic right now, and I started 1,400 seeds of that CBG strain. So, Im in the pheno-hunt of 1,400 plants, which is a crazy task to try to narrow that down to which is the one or two or three mothers that you want to keep, said Eaton.

But this isnt just getting the right genetic mix, its also about how a grower cares for his plants -- which affects how the genes are expressed. The trick with genes is that they will turn on or turn off depending on the environment.

Thats what these farmers really need to know, warned Ted Duerr. Certain genetics you cant just let it go to full maturity. Most of the genetics out there will go hot.

With hemp, if you leave the crop in the field too long or dont water it on time, the plant can build up too much THC, known as going hot in the industry.

There was some fields that we knew, and they did not water them, and they ended up getting hotter than other fields that Ive seen, he said.

Brett Eaton doesnt know of a hemp variety that makes over 5% CBD that wont go hot in the field. He only grows plants for cannabinoids in a greenhouse, where he can closely monitor the environmental conditions.

Ted Duerr

Some states have asked for a THC variance up to 1% only 11 Colorado hemp fields would have been destroyed last year had this been the case. The Colorado Department of Agriculture is interested, but they said growers will need to wait for the next farm bill to pass in 2023 before any changes to THC limits come into effect.

Farmers arent used to growing hermaphroditic crops that pose a legal threat. So, Duerr has a simple piece of advice for those thinking about growing hemp: Dont go too big." He says maybe start with an acre and see how it turns out.

Read more:
Unpredictable Biology And Stringent Regulations Turn Up The Heat For Hemp Farmers - KUNC

Recommendation and review posted by Bethany Smith

The core of this project is the heart. As humans, we can understand that heart rate tells us a lot about our emotions and how we feel in each life situation. Since we dont speak the language of animals, we need projects like this to better understand how they perceive their environments, so we can use that information to help them thrive.

Only 3% of the natural habitat available for maned wolves in Brazil is inside protected areas. That means animals are also living in areas where encounters with humans, vehicles and farming machinery are common and stress levels are higher. When sugar cane fields are harvested, for example, wolves can lose all their vegetation cover and food resources in less than 24 hours.

Having objective measurements of stress levels, and an understanding of where and how wolves move, could help us and land owners think about managing the land in ways that are more beneficial to wildlife. Our main goal is to become experts in the use of this technology, so we can apply it to the conservation of maned wolves and other endangered species in the wild. Studying the animals at SCBI has provided us with the skills we need, as well as the opportunity to overcome any obstacles in a controlled and safe environment.

This project is an excellent example of how much we can accomplish when we work as a team. We are physiologists, ecologists, biologists, veterinarians, animal care staff, students, donors, partners and more, all coming together to make this work possible. After a successful start, were expanding our scientific research at SCBI to other species, including eight scimitar-horned oryx. We proved that heart monitors can be safely used in maned wolves, and generated valuable information to compare with wild wolves. In 2021, we plan to start a field study with maned wolves in Brazil.

The Rhythm of Life Project was made possible with generous support from Medtronic.

View post:
A Heart to Heart with Maned Wolves | Smithsonian's National Zoo - Smithsonian's National Zoo and Conservation Biology Institute

Recommendation and review posted by Bethany Smith

1. 'CRISPR babies' are still too risky, says influential panel  Nature.com
2. Panel Lays Out Guidelines for CRISPR-Edited Human Embryos  The Scientist
3. Panel Lays Out Gene Editing Guidelines, Condemns Risk of Creating 'CRISPR' Babies  BioSpace
4. Closely-watched international CRISPR ethics panel leaves door ajar for germline editing one day  Endpoints News
5. CRISPR: Still too soon to try altering human embryo DNA, experts say  Hindustan Times
6. View Full Coverage on Google News

Read more:
'CRISPR babies' are still too risky, says influential panel - Nature.com

Recommendation and review posted by Bethany Smith

ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020, at 11:20 a.m. ET.

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel Eides WCG on behalf of CRISPR+1-617-337-4167reides@wcgworld.com

Read more:
CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference - Yahoo Finance

Recommendation and review posted by Bethany Smith

Global CRISPR Technology industry report about In-depth Research, estimates Revenue, and forecasts Growth Details in segments, regional, and research scope, historical data, Key Player and Growth Value.

The Global CRISPR Technology Market 2020 analysis provides a basic summary of the trade as well as definitions, classifications, applications and business chain structure. The worldwide CRISPR Technology marketing research is provided for the international markets together with development trends, competitive landscape analysis, and key regions development standing. Development policies and plans are mentioned similarly as producing processes and value structures are analyzed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue, and gross margins.

Premium Insights on CRISPR Technology Market 2020 with Market Players PositioningGet Exclusive Sample PDF Copy:https://inforgrowth.com/sample-request/6475179/crispr-technology-market

Major Classifications of CRISPR Technology Market:

Major Key players covered in this report:

By Product Type:

By Applications:

Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players Listhttps://inforgrowth.com/discount/6475179/crispr-technology-market

Impact of COVID-19:CRISPR Technology Market report analyses the impact of Coronavirus (COVID-19) on the CRISPR Technology industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the CRISPR Technology market in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get Sample Table of Content PDF of COVID-19/CoronaVirus Impact Analysis of CRISPR Technology Market 2020.https://inforgrowth.com/CovidImpact-Request/6475179/crispr-technology-market

This Market Study covers the CRISPR Technology Market Size across segments. It aims at estimating the market size and the growth potential of the market across segments by component, data type, deployment type, organization size, vertical, and region. This CRISPR Technology study also includes an in-depth competitive analysis of the key market players, along with their company profiles, key observations related to product and business offerings, recent developments, and key market strategies.

Attributes such as new development in CRISPR Technology market, Total Revenue, sales, annual production, government norm, and trade barriers in some countries are also mentioned in detail in the report. CRISPR Technology Report discusses about recent product innovations and gives an overview of potential regional market shares.

Reason to purchase CRISPR Technology market report:

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898

See original here:
CRISPR Technology Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or Loose out From the Impact of...

Recommendation and review posted by Bethany Smith

The report offers a far-reaching analysis of CRISPR And CRISPR-Associated (Cas) Genes industry, standing on the readers perspective, conveying definite market information, and adding valuable & knowledgeable data. It surveys the effect of the mechanical advancements, changes in speculation propensities, and top to the bottom outline of Product Specification.

Competitive Landscape:Geographically, the global CRISPR And CRISPR-Associated (Cas) Genes market is analysed by top manufacturers (production, price, revenue (value), and market share). The competitive analysis of leading market players is another notable feature of this report; it identifies direct or indirect competitors in the market are Caribou Biosciences, Addgene, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, CRISPR THERAPEUTICS, GE Healthcare Dharmacon

Request Free Sample Report at https://www.regalintelligence.com/request-sample/93953

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this CRISPR And CRISPR-Associated (Cas) Genes Market report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealers, and traders, as well as the raw materials suppliers, and producers, etc.

The primary sources from the demand side include CRISPR And CRISPR-Associated (Cas) Genes industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, End-User (product buyers), and related key executives from various key companies and organizations operating in the global CRISPR And CRISPR-Associated (Cas) Genes market.

Primary Types of the industry are Type 1, Type 2

Primary Applications of the industry are Application 1, Application 2

This report is based on the synthesis, analysis, and interpretation of information collected on the CRISPR And CRISPR-Associated (Cas) Genes market from various sources. Our analysts have analysed the information & data and gained insights using a mix of primary and secondary research efforts with the primary objective to provide a holistic view of the CRISPR And CRISPR-Associated (Cas) Genes Industry.

Ask For Table of [emailprotected] https://www.regalintelligence.com/request-toc/93953

The following market parameters were considered to estimate market value:

Market Overview

The report includes overviews market introduction, market drivers & influencing factors, restraints & challenges, and potential growth opportunities of CRISPR And CRISPR-Associated (Cas) Genes market. The report consists of market evaluation tools such as Porters five forces, PESTLE Analysis, and value chain analysis.

Table of Content

Chapter 1 About the CRISPR And CRISPR-Associated (Cas) Genes Industry1.1 Industry Definition and Types1.2 Main Market Activities1.3 Similar Industries1.4 Industry at a Glance

Chapter 2 World Market Competition Landscape2.1 CRISPR And CRISPR-Associated (Cas) Genes Markets by Regions2.1.1 USAMarket Revenue (M USD) and Growth Rate 2014-2019Sales and Growth Rate 2014-2019Major Players2.1.2 EuropeMarket Revenue (M USD) and Growth Rate 2014-2019Sales and Growth Rate 2014-2019Major Players2.1.3 ChinaMarket Revenue (M USD) and Growth Rate 2014-2019Sales and Growth Rate 2014-2019Major Players2.1.4 IndiaMarket Revenue (M USD) and Growth Rate 2014-2019Sales and Growth Rate 2014-2019Major Players2.1.5 JapanMarket Revenue (M USD) and Growth Rate 2014-2019Sales and Growth Rate 2014-2019Major Players2.1.6 South East AsiaMarket Revenue (M USD) and Growth Rate 2014-2019Sales and Growth Rate 2014-2019Major Players2.2 World CRISPR And CRISPR-Associated (Cas) Genes Market by Types2.3 World CRISPR And CRISPR-Associated (Cas) Genes Market by Applications2.4 World CRISPR And CRISPR-Associated (Cas) Genes Market Analysis2.4.1 World CRISPR And CRISPR-Associated (Cas) Genes Market Revenue and Growth Rate 2014-20192.4.2 World CRISPR And CRISPR-Associated (Cas) Genes Market Consumption and Growth rate 2014-20192.4.3 World CRISPR And CRISPR-Associated (Cas) Genes Market Price Analysis 2014-2019

Chapter 3 World CRISPR And CRISPR-Associated (Cas) Genes Market share3.1 Major Production Market share by Players3.2 Major Revenue (M USD) Market share by Players3.3 Major Production Market share by Regions in 2019, Through 20243.4 Major Revenue (M USD) Market share By Regions in 2019, Through 2024

Chapter 4 Supply Chain Analysis4.1 Industry Supply chain Analysis4.2 Raw material Market Analysis4.2.1 Raw material Prices Analysis 2014-20194.2.2 Raw material Supply Market Analysis4.2 Manufacturing Equipment Suppliers Analysis4.3 Production Process Analysis4.4 Production Cost Structure Benchmarks4.5 End users Market Analysis

Chapter 5 Company Profiles5.1 Caribou Biosciences5.1.1 Company Details (Foundation Year, Employee Strength and etc)5.1.2 Product Information (Picture, Specifications and Applications)5.1.3 Revenue (M USD), Price and Operating Profits5.2 Addgene5.2.1 Company Details (Foundation Year, Employee Strength and etc)5.2.2 Product Information (Picture, Specifications and Applications)5.2.3 Revenue (M USD), Price and Operating Profits5.3 Merck KGaA5.3.1 Company Details (Foundation Year, Employee Strength and etc)5.3.2 Product Information (Picture, Specifications and Applications)5.3.3 Revenue (M USD), Price and Operating Profits5.4 Mirus Bio LLC5.4.1 Company Details (Foundation Year, Employee Strength and etc)5.4.2 Product Information (Picture, Specifications and Applications)5.4.3 Revenue (M USD), Price and Operating Profits5.5 Editas Medicine5.5.1 Company Details (Foundation Year, Employee Strength and etc)5.5.2 Product Information (Picture, Specifications and Applications)5.5.3 Revenue (M USD), Price and Operating Profits5.6 Takara Bio USA5.6.1 Company Details (Foundation Year, Employee Strength and etc)5.6.2 Product Information (Picture, Specifications and Applications)5.6.3 Revenue (M USD), Price and Operating Profits5.7 Thermo Fisher Scientific5.7.1 Company Details (Foundation Year, Employee Strength and etc)5.7.2 Product Information (Picture, Specifications and Applications)5.7.3 Revenue (M USD), Price and Operating Profits5.8 Horizon Discovery Group5.8.1 Company Details (Foundation Year, Employee Strength and etc)5.8.2 Product Information (Picture, Specifications and Applications)5.8.3 Revenue (M USD), Price and Operating Profits5.9 Intellia Therapeutics5.9.1 Company Details (Foundation Year, Employee Strength and etc)5.9.2 Product Information (Picture, Specifications and Applications)5.9.3 Revenue (M USD), Price and Operating Profits5.10 CRISPR THERAPEUTICS5.10.1 Company Details (Foundation Year, Employee Strength and etc)5.10.2 Product Information (Picture, Specifications and Applications)5.10.3 Revenue (M USD), Price and Operating Profits5.11 GE Healthcare Dharmacon5.11.1 Company Details (Foundation Year, Employee Strength and etc)5.11.2 Product Information (Picture, Specifications and Applications)5.11.3 Revenue (M USD), Price and Operating Profits

For more information and discount on this report, reach us at: https://www.regalintelligence.com/check-discount/93953

Thank you for reading this article.

Read the original:
CRISPR And CRISPR-Associated (Cas) Genes Market Analysis Focusing on the Key Issues Surrounding the Growth of the Industry and Further Develop...

Recommendation and review posted by Bethany Smith

Overall market sentiment has been down on Crispr Therapeutics AG (CRSP) stock lately. CRSP receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.

Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.

InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.

Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

Crispr Therapeutics AG (CRSP) stock is trading at $83.11 as of 3:27 PM on Friday, Sep 4, a drop of -$2.58, or -3.01% from the previous closing price of $85.69. The stock has traded between $76.71 and $87.00 so far today. Volume today is elevated. So far 1,357,043 shares have traded compared to average volume of 880,219 shares.

To screen for more stocks like Crispr Therapeutics AG click here.

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

Go here to see the original:
Is it Time to Dump Crispr Therapeutics AG (CRSP) Stock After it Is Lower By 8.38% in a Week? - InvestorsObserver

Recommendation and review posted by Bethany Smith

Cell Theraputics Market

Los Angeles, United State, ,-The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global Cell Theraputics market. It sheds light on how the global Cell Theraputics market is expected to grow during the course of the forecast period. With SWOT analysis and Porters Five Forces analysis, it gives a deep explanation of the strengths and weaknesses of the global Cell Theraputics market and different players operating therein. The authors of the report have also provided qualitative and quantitative analyses of several microeconomic and macroeconomic factors impacting the global Cell Theraputics market. In addition, the research study helps to understand the changes in the industry supply chain, manufacturing process and cost, sales scenarios, and dynamics of the global Cell Theraputics market.

Get PDF template of this report:https://www.qyresearch.com/sample-form/form/1663874/global-cell-theraputics-market

Each player studied in the report is profiled while taking into account its production, market value, sales, gross margin, market share, recent developments, and marketing and business strategies. Besides giving a broad study of the drivers, restraints, trends, and opportunities of the global Cell Theraputics market, the report offers an individual, detailed analysis of important regions such as North America, Europe, and Asia Pacific. Furthermore, important segments of the global Cell Theraputics market are studied in great detail with key focus on their market share, CAGR, and other vital factors.

Key Players:

Bristol-Myers Squibb Company (Celgene), Bluebird Bio, Crispr Therapeutics, Roche (Spark Therapeutics), PTC Therapeutics, Moderna Therapeutics, Quanterix, Brainstorm Cell Therapeutics Inc., Lineage Cell Therapeutics, Cti Biopharma, Atara Biotherapeutics, Inc, Adaptimmune

Type Segments:

Stem Cells, Immunocyte

Application Segments:

Allogeneic Cell Therapy, Autologous Cell Therapy, Xenogeneic Cell Therapy

Regional Segments

Table of Contents

1 Market Overview of Cell Theraputics1.1 Cell Theraputics Market Overview1.1.1 Cell Theraputics Product Scope1.1.2 Market Status and Outlook1.2 Global Cell Theraputics Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Cell Theraputics Market Size by Region (2015-2026)1.4 Global Cell Theraputics Historic Market Size by Region (2015-2020)1.5 Global Cell Theraputics Market Size Forecast by Region (2021-2026)1.6 Key Regions Cell Theraputics Market Size YoY Growth (2015-2026)1.6.1 North America Cell Theraputics Market Size YoY Growth (2015-2026)1.6.2 Europe Cell Theraputics Market Size YoY Growth (2015-2026)1.6.3 China Cell Theraputics Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Cell Theraputics Market Size YoY Growth (2015-2026)1.6.5 Latin America Cell Theraputics Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Cell Theraputics Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Cell Theraputics Industry Impact1.7.1 How the Covid-19 is Affecting the Cell Theraputics Industry

1.7.1.1 Cell Theraputics Business Impact Assessment Covid-19

1.7.1.2 Supply Chain Challenges

1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Cell Theraputics Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-19

1.7.3.1 Government Measures to Combat Covid-19 Impact

1.7.3.2 Proposal for Cell Theraputics Players to Combat Covid-19 Impact 2 Cell Theraputics Market Overview by Type2.1 Global Cell Theraputics Market Size by Type: 2015 VS 2020 VS 20262.2 Global Cell Theraputics Historic Market Size by Type (2015-2020)2.3 Global Cell Theraputics Forecasted Market Size by Type (2021-2026)2.4 Stem Cells2.5 Immunocyte 3 Cell Theraputics Market Overview by Type3.1 Global Cell Theraputics Market Size by Application: 2015 VS 2020 VS 20263.2 Global Cell Theraputics Historic Market Size by Application (2015-2020)3.3 Global Cell Theraputics Forecasted Market Size by Application (2021-2026)3.4 Allogeneic Cell Therapy3.5 Autologous Cell Therapy3.6 Xenogeneic Cell Therapy 4 Global Cell Theraputics Competition Analysis by Players4.1 Global Cell Theraputics Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cell Theraputics as of 2019)4.3 Date of Key Manufacturers Enter into Cell Theraputics Market4.4 Global Top Players Cell Theraputics Headquarters and Area Served4.5 Key Players Cell Theraputics Product Solution and Service4.6 Competitive Status4.6.1 Cell Theraputics Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Bristol-Myers Squibb Company (Celgene)5.1.1 Bristol-Myers Squibb Company (Celgene) Profile5.1.2 Bristol-Myers Squibb Company (Celgene) Main Business and Companys Total Revenue5.1.3 Bristol-Myers Squibb Company (Celgene) Products, Services and Solutions5.1.4 Bristol-Myers Squibb Company (Celgene) Revenue (US$ Million) (2015-2020)5.1.5 Bristol-Myers Squibb Company (Celgene) Recent Developments5.2 Bluebird Bio5.2.1 Bluebird Bio Profile5.2.2 Bluebird Bio Main Business and Companys Total Revenue5.2.3 Bluebird Bio Products, Services and Solutions5.2.4 Bluebird Bio Revenue (US$ Million) (2015-2020)5.2.5 Bluebird Bio Recent Developments5.3 Crispr Therapeutics5.5.1 Crispr Therapeutics Profile5.3.2 Crispr Therapeutics Main Business and Companys Total Revenue5.3.3 Crispr Therapeutics Products, Services and Solutions5.3.4 Crispr Therapeutics Revenue (US$ Million) (2015-2020)5.3.5 Roche (Spark Therapeutics) Recent Developments5.4 Roche (Spark Therapeutics)5.4.1 Roche (Spark Therapeutics) Profile5.4.2 Roche (Spark Therapeutics) Main Business and Companys Total Revenue5.4.3 Roche (Spark Therapeutics) Products, Services and Solutions5.4.4 Roche (Spark Therapeutics) Revenue (US$ Million) (2015-2020)5.4.5 Roche (Spark Therapeutics) Recent Developments5.5 PTC Therapeutics5.5.1 PTC Therapeutics Profile5.5.2 PTC Therapeutics Main Business and Companys Total Revenue5.5.3 PTC Therapeutics Products, Services and Solutions5.5.4 PTC Therapeutics Revenue (US$ Million) (2015-2020)5.5.5 PTC Therapeutics Recent Developments5.6 Moderna Therapeutics5.6.1 Moderna Therapeutics Profile5.6.2 Moderna Therapeutics Main Business and Companys Total Revenue5.6.3 Moderna Therapeutics Products, Services and Solutions5.6.4 Moderna Therapeutics Revenue (US$ Million) (2015-2020)5.6.5 Moderna Therapeutics Recent Developments5.7 Quanterix5.7.1 Quanterix Profile5.7.2 Quanterix Main Business and Companys Total Revenue5.7.3 Quanterix Products, Services and Solutions5.7.4 Quanterix Revenue (US$ Million) (2015-2020)5.7.5 Quanterix Recent Developments5.8 Brainstorm Cell Therapeutics Inc.5.8.1 Brainstorm Cell Therapeutics Inc. Profile5.8.2 Brainstorm Cell Therapeutics Inc. Main Business and Companys Total Revenue5.8.3 Brainstorm Cell Therapeutics Inc. Products, Services and Solutions5.8.4 Brainstorm Cell Therapeutics Inc. Revenue (US$ Million) (2015-2020)5.8.5 Brainstorm Cell Therapeutics Inc. Recent Developments5.9 Lineage Cell Therapeutics5.9.1 Lineage Cell Therapeutics Profile5.9.2 Lineage Cell Therapeutics Main Business and Companys Total Revenue5.9.3 Lineage Cell Therapeutics Products, Services and Solutions5.9.4 Lineage Cell Therapeutics Revenue (US$ Million) (2015-2020)5.9.5 Lineage Cell Therapeutics Recent Developments5.10 Cti Biopharma5.10.1 Cti Biopharma Profile5.10.2 Cti Biopharma Main Business and Companys Total Revenue5.10.3 Cti Biopharma Products, Services and Solutions5.10.4 Cti Biopharma Revenue (US$ Million) (2015-2020)5.10.5 Cti Biopharma Recent Developments5.11 Atara Biotherapeutics, Inc5.11.1 Atara Biotherapeutics, Inc Profile5.11.2 Atara Biotherapeutics, Inc Main Business and Companys Total Revenue5.11.3 Atara Biotherapeutics, Inc Products, Services and Solutions5.11.4 Atara Biotherapeutics, Inc Revenue (US$ Million) (2015-2020)5.11.5 Atara Biotherapeutics, Inc Recent Developments5.12 Adaptimmune5.12.1 Adaptimmune Profile5.12.2 Adaptimmune Main Business and Companys Total Revenue5.12.3 Adaptimmune Products, Services and Solutions5.12.4 Adaptimmune Revenue (US$ Million) (2015-2020)5.12.5 Adaptimmune Recent Developments 6 North America Cell Theraputics by Players and by Application6.1 North America Cell Theraputics Market Size and Market Share by Players (2015-2020)6.2 North America Cell Theraputics Market Size by Application (2015-2020) 7 Europe Cell Theraputics by Players and by Application7.1 Europe Cell Theraputics Market Size and Market Share by Players (2015-2020)7.2 Europe Cell Theraputics Market Size by Application (2015-2020) 8 China Cell Theraputics by Players and by Application8.1 China Cell Theraputics Market Size and Market Share by Players (2015-2020)8.2 China Cell Theraputics Market Size by Application (2015-2020) 9 Rest of Asia Pacific Cell Theraputics by Players and by Application9.1 Rest of Asia Pacific Cell Theraputics Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Cell Theraputics Market Size by Application (2015-2020) 10 Latin America Cell Theraputics by Players and by Application10.1 Latin America Cell Theraputics Market Size and Market Share by Players (2015-2020)10.2 Latin America Cell Theraputics Market Size by Application (2015-2020) 11 Middle East & Africa Cell Theraputics by Players and by Application11.1 Middle East & Africa Cell Theraputics Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Cell Theraputics Market Size by Application (2015-2020) 12 Cell Theraputics Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

Key Questions Answered

Research Methodology

QY Research uses trustworthy primary and secondary research sources to compile its reports. It also relies on latest research techniques to prepare highly detailed and accurate research studies such as this one here. It uses data triangulation, top down and bottom up approaches, and advanced research processes to come out with comprehensive and industry-best market research reports.

Enquire for customization in Report Cell Theraputicshttps://www.qyresearch.com/customize-request/form/1663874/global-cell-theraputics-market

About Us

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Read more from the original source:
Cell Theraputics Market Status, Players, Types, Applications, and Forecast 2020-2026-Crispr Therapeutics, Roche (Spark Therapeutics), PTC Therapeutics...

Recommendation and review posted by Bethany Smith

The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism

Roots Analysis has announced the addition of Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)) report to its list of offerings.

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

Over 280 stem cell therapies are under development, most of which are allogeneic productsMore than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.

70% of pipeline candidates are based on mesenchymal stem cellsIt is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.

Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regionsWithin these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies

Over 1,500 grants were awarded for stem cell research, since 2015More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.

Outsourcing has become indispensable to R&D and manufacturing activity in this domainPresently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.

North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.

For additional details, please visithttps://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html

or email [emailprotected]

You may also be interested in the following titles:

Contact:

Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 1091[emailprotected]

The rest is here:
Market Growth of Global Stem Cells to Remain Sluggish through 2020 2030 - The News Brok

Recommendation and review posted by Bethany Smith

Global Coronavirus pandemic has impacted all industries across the globe, Progenitor Cell Product market being no exception. As Global economy heads towards major recession post 2009 crisis, Cognitive Market Research has published a recent study which meticulously studies impact of this crisis on Global Progenitor Cell Product market and suggests possible measures to curtail them. This press release is a snapshot of research study and further information can be gathered by accessing complete report. To Contact Research Advisor Mail us @ [emailprotected] or call us on +1-312-376-8303.

Report is a detailed study of the Progenitor Cell Product market, which covers all the essential information required by a new market entrant as well as the existing players to gain a deeper understanding of the market. Report has been segmented into Geographical Segmentation, Key players, Key Topics Industry Value and Demand Analysis Forecast to 2027 and provides comprehensive investigation.

Global Progenitor Cell Product Market: Product analysis: Pancreatic progenitor cells, Cardiac Progenitor Cells, Intermediate progenitor cells, Neural progenitor cells (NPCs), Endothelial progenitor cells (EPC), Others

Global Progenitor Cell Product Market: Application analysis: Medical care, Hospital, Laboratory

Major Market Players with an in-depth analysis: NeuroNova AB, StemCells, ReNeuron Limited, Asterias Biotherapeutics, Thermo Fisher Scientific, STEMCELL Technologies, Axol Bio, R&D Systems, Lonza, ATCC, Irvine Scientific, CDI

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Progenitor Cell Product Market Report 2020 (Coronavirus Impact Analysis on Progenitor Cell Product Market)

The research comprises primary information about the products. Similarly, it includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of Progenitor Cell Product market. Additionally, report provides market drivers and challenges & opportunities for overall market in the particular provincial sections.

The report gives detailed account on each segment which helps to understand market more effectively. The company profiling of key players include: business overview, product description, research and development investment, key development, business strategy, and SWOT analysis. It also involves sales revenue of each division and geographical coverage for two consecutive years.

Request Free Sample Copy of Progenitor Cell Product Market Research [emailprotected] https://cognitivemarketresearch.com/pharma-%26-healthcare/progenitor-cell-product-market-report#download_report

The industry intelligence study of the Progenitor Cell Product market covers the estimation size of the market each in phrases of value (Mn/Bn USD) and volume (x units). Further, report consists of Porters Five Forces and BCG matrix as well as product life cycle to help you in taking wise decisions. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Regional Analysis for Progenitor Cell Product Market:North America (United States, Canada)Europe (Germany, Spain, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, India, Australia, and South Korea)Latin America (Brazil, Mexico, etc.)The Middle East and Africa (GCC and South Africa)

Get A Free Sample of Progenitor Cell Product Market Report: https://cognitivemarketresearch.com/pharma-%26-healthcare/progenitor-cell-product-market-report#download_report

About Us:Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: [emailprotected]Web: https://www.cognitivemarketresearch.com/

Continued here:
Global and Asia Pacific Progenitor Cell Product Market to Witness Huge Growth by 2027 Major Manufacturers included in report NeuroNova AB, StemCells,...

Recommendation and review posted by Bethany Smith

September 2, 2020 An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by 34 per cent the number of serious adverse events following balloon angioplasty, a treatment for the most common form of heart disease.

For patients undergoing percutaneous coronary intervention (PCI), the choice of antiplatelet therapy can be critical to post treatment success, and to minimize the chance of heart attack or stroke.

The TAILOR-PCI trial, co-led by principal investigators Michael Farkouh, M.D., cardiologist and Multinational Clinical Trials Chair at the Peter Munk Cardiac Centre and director of the Heart and Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research, University of Toronto, and Naveen Pereira, M.D., professor of medicine and cardiologist at Mayo Clinic, studied the effectiveness of genetic-guided therapy in patients that have had PCIs when compared to conventional therapy.

The trial introduces the concept and validates the approach to personalized medicine when it comes to antiplatelet therapy, and therefore allows our physicians to potentially change their practice based on the needs of patients undergoing PCI, Farkouh said. This will potentially inform the kinds of therapies patients with heart disease are prescribed after PCI world-wide.

Placement of a balloon and metal stent inside a heart artery can irritate the blood vessel and cause it to clot, which can block the artery from being treated. PCI patients are prescribed medications to prevent their blood from clotting the most common medication used is clopidogrel, which stops blood platelets from sticking together and prevents clots from forming. However, in almost a third of all patients, the gene (CYP2C19) required to activate clopidogrel does not work.

As a result, patients with this genetic variant may be at a higher risk of experiencing adverse cardiovascular events, such as heart attack or stroke in the year following their procedure.

Current guidelines do not recommend genetic testing when prescribing clopidogrel, and the trial was designed to determine if genetic testing would decrease cardiovascular complications after PCI.

The Journal of the American Medical Association (JAMA) published the results of the TAILOR-PCI trial on Aug. 25, 2020.[1] The trial enrolled 5,302 patients treated for heart artery blockage with one or more stents, and followed them for one year.

Half the group was tested for the CYP2C19 gene variation, and carriers (35%) were treated with the alternative anti-platelet medication, Ticagrelor. The remainder of the group was given Clopidogrel, as was the entire control group of patients who did not receive genetic testing before PCI.

Although the TAILOR-PCI trial did not meet its primary endpoint of demonstrating a 50 per cent reduction at one-year post-procedure, trends did show a benefit towards genetic testing with a 34 per cent reduction in serious adverse cardiovascular events.

Although these results fell short of the effect size that we predicted, they nevertheless provide a signal that offers support for the benefit of genetically guided therapy, with approximately one third fewer adverse events in the patients who received genetically guided treatment compared with those who did not, Pereira said.

A post-hoc analysis of the trial also showed a nearly 80% reduction in the rate of adverse events in the first three months of treatment among patients who received genetically guided therapy compared with those who did not.

Since the studys design in 2012, the standard of care following PCIs has greatly improved. Drug-coated stents and other treatments have reduced the rate of adverse events for patients in a year, but at the same time made it more difficult for the trial to reach its goal.

The trial is currently undergoing an extended follow-up beyond the original 12-month period.

The study was funded by Mayo Clinic, Mayo Clinic Center for Individualized Medicine and the National Heart, Lung and Blood Institute. Spartan Bioscience Inc. supplied the point-of-care genetic tests used.

Find more news on antiplatelet therapies

Reference:

1. Naveen L. Pereira, Michael E. Farkouh, Derek So, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionThe TAILOR-PCI Randomized Clinical Trial. JAMA. 2020;324(8):761-771. doi:10.1001/jama.2020.12443.

View original post here:
Trial Shows Benefit of Using Genetic Testing to Tailor Antiplatelet Therapy - Diagnostic and Interventional Cardiology

Recommendation and review posted by Bethany Smith

A Boston consumer genetics company that has batted away former employees accusations of shoddy practices since at least 2019 is now under investigation by the state Department of Public Health for logging hundreds of false positive coronavirus test results, including some in Fall River and Taunton.

The company, Orig3n, has halted COVID-19 testing in the state. A company spokesman said the false positives were due to human error in processing the tests.

In August, after learning about the Massachusetts investigation, North Carolina issued a stop order for its coronavirus testing contract with the company, Orig3n.

The consumer genetics start-up, which claims it can tell customers what kind of foods they should eat and whether theyre predisposed to intelligence based on their DNA, has secured some of the biggest coronavirus testing contracts in the country.

According to an Orig3n spokesman, the company continues to offer COVID-19 testing elsewhere in the U.S.

So far, the Massachusetts DPH has found Orig3n sent out more than 300 COVID-19 tests wrongly classified as positive in Massachusetts, a number that could increase as DPH staff continue investigating. Orig3n claims the company isnt aware of any additional false positives. According to a Harvard epidemiologist and lab director, false negatives are far more difficult to discover, because most tests come back as negative.

Ted Owens, CEO at North Hills Pines Edge skilled nursing facility in Needham, one of roughly 60 long-term care facilities that used Orig3n test services, said in an Aug. 11 bulletin to residents and staff that Orig3n returned a total of 19 false positives to the nursing home.

The numbers didnt seem credible to Owens, but Pines Edge began immediately to take actions based on the working assumption that we needed to treat these results as correct.

It turned out that several other skilled nursing facilities also showed an unusual spike in positive cases last week, and oddly enough, all these facilities had used the same testing vendor, Owens continued. This caught the attention of the epidemiologists at Mass DPH, who intervened and instructed the vendor to re-test the samples.

Upon retesting, all of the positive tests were found to be negative.

The spike in cases -- which turned out to be false positives -- caused a panic in Needham. They came as the school district made plans to return to in-person learning, and a public health nurse for the town was asked to appear before its Select Board.

Needham Public Health Nurse Tiffany Zike told the Board on Aug. 18 that a number of coronavirus cases reported in July were considered false cases that were revoked due to the lab having an issue.

A $25,000 wire transfer

In early May, nursing homes across Massachusetts were looking for a miracle.

The Massachusetts DPH had ordered long-term care facilities coping with severe coronavirus outbreaks to test 90% of residents and staff for COVID-19 by May 25 in order to qualify for a portion of the $130 million in relief funding offered by the state.

Many nursing homes struggled to meet the deadline because of a shortage of COVID-19 tests. The National Guard was testing nursing home residents and staff on behalf of the state, but demand was high.

When Ron Doty got a memo from the Massachusetts Senior Care Association on May 6 offering Orig3n as a turnkey mobile testing option, he immediately reached out to the company.

Doty, administrator at Marlborough Hills Rehabilitation & Health Care Center in Marlborough, wired $25,000 to Orig3n. The next day, he received 250 COVID-19 test kits from the company.

Two months later, Orig3n was asked to suspend COVID-19 testing in Massachusetts, which it did on Aug. 8. Staff at the Massachusetts DPH noticed the lab was reporting an unusually high rate of positive tests, prompting the agency to investigate, according to a DPH spokesperson.

The state DPH declined to identify which nursing homes used Orig3ns testing services, citing the ongoing investigation.

Tony Plohoros, Orig3ns spokesman, said the lab is now working with state health officials to correct problems in its Boston lab, which has ceased processing coronavirus samples but continues to process consumer genetic profiles.

While it remains unclear if the federal government has taken action to halt use of Orig3ns COVID-19 testing services in other parts of the country, as North Carolina did, concerns about Orig3n hadnt yet reached a health care supply company in Ohio as of this week. That company, Link-age Solutions, is still working with Orig3n to provide coronavirus tests to long-term care facilities nationwide.

Patrick Schwartz, a spokesman for Link-age Solutions, said Thursday the company was unaware Orig3n was asked to cease coronavirus testing in Massachusetts.

One of the highest accuracy ratings in the market

Orig3n received an emergency authorization to conduct COVID-19 testing from the Food & Drug Administration in April.

The same month, the company received a federal Paycheck Protection Program loan valued between $350,000 and $1 million from Silicon Valley Bank, according to U.S. Treasury data.

Since getting the FDA approval, Orig3n has provided testing services to The New England Power Generators Association, Bostons homeless population, a boarding school in Virginia, and other public and private entities.

In late June, Link-age Solutions, a Mason, Ohio-based company that helps long-term care facilities nationwide obtain supplies ranging from pharmaceuticals to office supplies issued a press release touting Orig3ns breakthrough testing method as having one of the highest accuracy ratings in the market.

In partnering with Orig3n, Link-age could offer in-demand coronavirus tests to its members at a reduced cost, according to the press release. Results would be returned less than 36 hours after specimens arrived at the lab, the release said.

The lab boasts output capabilities of 6,000 and up to 12,000 tests per day, and will offer billing to Medicare where appropriate, the press release stated. Reporters questions to the Centers for Medicare & Medicaid Services have gone unanswered.

Schwartz, the Link-age spokeman, said Thursday his company continues to offer COVID-19 testing services performed by Orig3n, and that feedback about Orig3ns tests from its customers has been positive.

Company flagged in the past

Orig3n lists its office location as the third floor of 27 Drydock Ave. in the heart of Bostons Seaport. Until August, thats where the company processed its coronavirus tests.

Before it got into the coronavirus business, Orig3n billed itself as a consumer genetics pioneer, carving a path toward a future of wellness and health through the use of diagnostics, genetics and biotechnology.

The company, founded in 2014, offers tests ranging in cost from $29 to $298 that are supposed to help people learn what kinds of food, exercise and beauty products would work best for their genetic profiles, and even whether they are genetically predisposed to so-called superhero traits including intelligence and strength, according to Bloomberg Businessweek.

A former Orig3n employee who spoke to Gannett New England reporters on the condition of anonymity because of a nondisclosure agreement with the company said the number one complaint received by customer service was genetic profile tests not being returned to customers. The employee, who left the company pre-pandemic, didnt think the company could handle both genetic profile testing and coronavirus testing.

Unless things drastically changed since I have left, not even testing, just bandwidth-wise, they were already kind of drowning when I left, the employee said.

Despite its start-up status, Orig3n quickly gained prominence partly through securing big-name partnerships, including one with the NFLs Baltimore Ravens.

In September 2017, the Ravens linked up with Orig3n for an event called DNA Day. Roughly 70,000 Ravens fans were set to pour into the teams stadium, where they could have picked up a free genetic testing kit.

The event never happened. The Ravens postponed it days before federal health officials told The Baltimore Sun they were, working to determine whether any of the testing being offered by Orig3n is subject to the requirements of the Clinical Laboratory Improvement Amendments of 1988.

The federal regulatory standards apply to labs testing human samples in the United States, and are intended to ensure accuracy, effectiveness and reliability.

About a year after DNA Day was scrapped, 17 former Orig3n employees criticized the company in Bloomberg Businessweek, alleging it, habitually cut corners, tampered with or fabricated results, and failed to meet basic scientific standards.

Marketing, not science, the employees said, was the companys priority.

Press releases put out by Orig3n throughout the pandemic show the company was eager to publicize contracts with respected institutions, both public and private.

On May 12, the company announced what it called a comprehensive solution to enable COVID-19 testing for Massachusetts nursing home residents.

In the press release, the company said it sought to become the partner of choice for coordinating and providing COVID-19 testing for defined populations beyond long-term care residents and employees, including private employers, schools, government agencies, and cities and states.

The nursing home program is one of many applications for Orig3ns fully-integrated solution, the press release said.

What went wrong?

Doty, the Marlborough nursing home administrator, would not have known about Orig3n if not for the May 6 memo from Massachusetts Senior Care Association, an organization many nursing homes relied on during the viruss spring surge in the state to interpret complex and shifting guidance from the DPH.

Massachusetts Senior Care Association President Tara Gregorio said in a statement that her organization essentially serves as a messenger for its members, and that it relies on governmental agencies to vet labs like Orig3n.

Throughout the pandemic, MSCA has passed along lists of government approved COVID-19 PCR testing labs options available to our members, Gregorio wrote. We must rely, as all providers do, on the licensing process to ensure legitimacy and accuracy of these labs.

The FDA, which gave Orig3n emergency authorization to conduct coronavirus testing last spring, has not yet responded to Gannett New England reporters seeking comment.

According to a Massachusetts DPH spokesman, Orig3n told the agency after it was contacted by DPH that errors in testing occurred because of a broken vial or contaminated plate during final processing, an explanation DPH investigators are now trying to confirm.

In an email to Gannett New England reporters on Friday, Plohoros, Orig3ns spokesman, said, human error at the beginning of the laboratory testing process caused a pre-extraction reagent that was used in the affected batch tests to become contaminated.

In an Aug. 18 press conference, Massachusetts Secretary of Health and Human Services Marylou Sudders said erroneous results from Orig3n affected the number of COVID-19 cases reported in Fall River and Taunton.

The positive test rates for that three-day period for that one lab just seemed high, and so (we) went back, and the lab stopped processing, theyre still not processing any tests, Sudders said, adding that DPH staff was analyzing tests processed prior to the discovery to make sure the issue was, as Orig3n told the DPH, a one-time problem rather than a more structural issue.

Dr. Michael Mina is an assistant professor of epidemiology at Harvard T. H. Chan School of Public Health who has experience running laboratories that perform PCR testing.

Mina says a lab that processes 6,000 to 12,000 PCR coronavirus tests a day as Orig3n has said it does would need to be run with what he called extreme quality control measures.

It requires an amazing amount of concentration and care to really ensure youre not getting contamination or any number of other problems that can happen, he said. If this was an easy (test), I would have said, sure, any lab can do it but this particular (test) ... it really is a finicky test. You have to be extremely careful about how youre doing it, and that means you need a lot of quality controls. You need to be a really diligent lab.

Mina, who stressed he has no knowledge of Orig3n other than circulating allegations that the company had previously been investigated, said when a mistake like the kind Orig3n described occurs, staff should immediately stop processing, sterilize the area and alert any affected patients and health departments.

The fact that the Massachusetts DPH noticed the problem and not Orig3n is a problem, Mina said.

That shows in general that the quality control wasnt being maintained, he said, adding that performing intense quality control checks multiple times daily is a core tenet of running any lab, especially a high-complexity clinical lab. And if were giving them the benefit of the doubt, they didnt know that there was a problem because otherwise its just nefarious.

Mina said that a professionally run lab would likely have caught the mistake, and alerted the state DPH immediately.

Part of the reason for that is simply a motive to care for the patient, who will likely make important decisions about their own behavior based on the test result they receive, which in turn affect other people.

At Brigham, for example, where I was one of the medical directors, of course people feel embarrassed (about making a mistake), but theres this strong culture where people recognize that their embarrassment is not worth a patients hardship, Mina said. Thats one thing that really, I think, lacks a little bit when we move into industry laboratories running clinical tests. That same spirit of honesty ... might not exist everywhere.

While mistakes at labs are common, Mina said, theyre also commonly fixed and they dont usually require an investigation.

Mina said that the U.S. did need to increase its capacity to process coronavirus tests this spring, but labs, especially ones new to the medical diagnostics space, as Orig3n is, need to be monitored closely.

Its just important to keep all these things in check, Mina said. The frenzy to do coronavirus testing has been so extreme. I dont think labs should be immediately shut down for mistakes, but we have to remain vigilant to ensure that all the testing that is being done is up to the highest standards.

Continue reading here:
Genetics start-up continues COVID-19 testing as DPH probes testing errors, including some in Fall River, Taunton - Taunton Daily Gazette

Recommendation and review posted by Bethany Smith

SAN FRANCISCO, Sept. 3, 2020 /PRNewswire/ --Invitae (NYSE: NVTA), a leading medical genetics company, today announced enrollment has begun for a nationwide study to better understand the role of current genetic testing guidelines in ensuring prostate cancer patients receive testing to identify clinically relevant genetic variants that can inform prognosis and support access to targeted therapies. The study is supported by Invitae and is part of the company's ongoing work to increase access to genetic information for men with prostate cancer.

"Currently, germline testing guidelines for patients with prostate cancer have evolved from more than one set of NCCN guidelines and some may still find these guidelines difficult to implement in everyday practice," said Neal D. Shore, M.D., F.A.C.S. from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and the principal investigator of the study. "Guidelines were established when testing was both more expensive and less accessible and don't address newer therapeutic approvals and trial literature for expanding therapeutic options, missing many patients whose clinical care and treatment choices could benefit from genetic information. Our study is intended to provide a deeper understanding of how these issues impact the care of men with prostate cancer so that we might improve how genetic information can be assessed and utilized for their cancer care and potentially inform their family members."

The use and importance of genetic information in the diagnosis and treatment of prostate cancer has been growing, particularly as the development of targeted treatments continues to accelerate. Despite its utility, guidelines governing testing among prostate cancer patients remain restrictive, and genetic information is underutilized in prostate cancer care. The study will determine whether guidelines are adequate in identifying patients who may benefit from genetic testing.

"Simplifying and possibly expanding current testing guidelines would provide benefits for medical management of men with prostate cancer and offer opportunities for targeted therapies, including PARP inhibitors and qualification for clinical trials," said Robert Nussbaum, M.D., chief medical officer of Invitae. "In addition, the genes involved in prostate cancer include BRCA1 and 2, which as we all know also play an important role in breast and ovarian cancer, and MSH6 and other genes involved in hereditary colon cancer. Widespread testing among men with prostate cancer could have an important role in not only improving their care but also the health of their relatives."

The study will enroll men across the country who have been diagnosed with prostate cancer. Both men who meet and don't meet current testing guidelines will be included to gather data on whether genetic testing results change treatment and recommendations. In addition, the study will also gather data on the patient's experience with genetic testing.

A study presented recentlyby Invitae at the American College of Medical Genetics and Genomics (ACMG) underscored the frequency of actionable variants expanded testing can help uncover. The study of 2,252 men found an overall positive rate of 13% with no statistical differences in rates among stages of disease. Only half of patients with an actionable variant reported a family history suggestive of increased risk. Nearly three-quarters (71%) of positive patients were eligible for management guidelines and/or potentially eligible for approved precision therapies or clinical trials.

An estimated three million men are living with prostate cancer in the U.S., and just under 200,000 are newly diagnosed each year.

Contact [emailprotected] for more information about the study.

About InvitaeInvitae Corporation(NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website atinvitae.com.

Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the use and importance of genetic testing and information; and the benefits of simplifying and possibly expanding current testing guidelines for men with prostate cancer. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Contact:Laura D'Angelo[emailprotected](628) 213-3283

SOURCE Invitae Corporation

http://www.invitae.com

Excerpt from:
Multi-site study to evaluate the role of testing guidelines in ensuring access to genetic information for men with prostate cancer - PRNewswire

Recommendation and review posted by Bethany Smith

TEMPLE CITY, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (Nasdaq: FLGT) and New York City Health and Hospitals have announced they will provide COVID-19 testing to hundreds of thousands of students across approximately 1600 locations as they return to school in September and over the next several months. Fulgent will provide its FDA EUA-approved at-home test, Picture by Fulgent, a RT-PCR test that provides the highest level of sensitivity and specificity, utilizing a self-collected nasal swab sample. Fulgent will provide results within 24-48 hours from the time when Fulgent receives and accepts a specimen for the test.

Fulgent is very happy to partner with the City of New York on such an important and novel testing protocol. Its an ambitious goal to test so many students in such a rapid fashion, but the combination of the Fulgent technology platform and lab capacity along with the strong testing infrastructure of New York City makes this possible, commented Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics. In just a few short days, we were able to get the first shipment of hundreds of thousands of Picture kits to New York City. We will now be working closely with the city on the distribution, return and replenishment of the kits, added Perthuis.

This is one of the first large-scale testing programs for COVID-19 to utilize an at-home test kit. Fulgents Picture Genetics at-home test was chosen due to its convenient self-administration, which can be used on-site at schools as well as at home. The companys industry-leading turnaround time of 24-48 hours also makes this a powerful tool for back-to-school testing.

About NYC Test & Trace Corps

The NYC Test & Trace Corps is a public health initiative to fight COVID-19 so that New Yorkers can get back to school, work and help New York City reopen safely. The Corps is a group of doctors, public health professionals and community advocates working to reverse the COVID-19 outbreak and protect our city. The public health program is led by NYC Health + Hospitals in close collaboration with the NYC Department of Health and Mental Hygiene and other city agencies. Through its robust and citywide partnerships, The Corps helps New Yorkers receive free, safe and confidential testing for COVID-19 and for the antibody test. It ensures that anyone with the virus receives care and can safely isolate to prevent the spread. For more information, visit https://www.nychealthandhospitals.org/test-and-trace/.

About Fulgent Genetics

Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (NGS) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Companys advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19), including NGS and reverse transcription polymerase chain reaction (RT-PCR) - based tests. The Company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Companys business is its ability to provide expansive options and flexibility for all clients unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

About Picture Genetics

Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from the ease and comfort of home, at an affordable price point. The Picture Genetics platform provides a holistic approach to at-home genetic screening by including oversight from independent physicians as well as genetic counseling options to complement Fulgent Genetics comprehensive genetic testing analysis. The Picture Genetics platform currently offers multiple tests, providing medically actionable, clinical-level results with professional medical follow-up in one easy process. Visit http://www.picturegenetics.comfor more information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: the companys identification and evaluation of opportunities and its ability to capitalize on opportunities to grow its business; expected future lab capacity and turnaround times; expectations or guidance regarding future revenues and managements judgements and evaluations of the companys platform and technology.

Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the companys future performance, and they are based on managements current assumptions, expectations and beliefs concerning future developments and their potential effect on the companys business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for its tests and the pandemics effects on the global supply chain; the market potential for, and the rate and degree of market adoption of, the companys tests, including its newly-developed tests for COVID-19 and genetic testing generally; the companys ability to capture a sizable share of the developing market for genetic and COVID-19 testing and to compete successfully in these markets, including its ability to continue to develop new tests that are attractive to its various customer markets, its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the companys ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the companys ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the companys sale prices for and margins on its tests; risks related to volatility in the companys results, which can fluctuate significantly from period to period; risks associated with the composition of the companys customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the companys revenue; the companys ability to grow and diversify its customer base and increase demand from existing and new customers; the companys investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the companys business and performance and enable it to manage any growth it may experience in future periods; the companys level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the companys level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the companys compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the companys international operations; the companys ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.

The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law.

The companys reports filed with the U.S. Securities and Exchange Commission (SEC), including its annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the companys website upon their filing with the SEC. These reports contain more information about the company, its business and the risks affecting its business.

Investor Relations Contact:The Blueshirt GroupMelanie Solomon, 415-217-4964, melanie@blueshirtgroup.com

Media Contact:The Blueshirt GroupJeff Fox, 415-828-8298, jeff@blueshirtgroup.com

Read the original:
Fulgent Genetics, New York City Health and Hospitals Partner on Large-Scale Back-to-School COVID-19 Testing - GlobeNewswire

Recommendation and review posted by Bethany Smith

TEMPLE CITY, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the company), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020. These representatives of the company will host a presentation beginning at 1:00 p.m. ET.

A live webcast of the presentation will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible on the Events section of the IR website beginning approximately one hour following the completion of the event.

About Fulgent Genetics

Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (NGS) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Companys advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19), including NGS and reverse transcription polymerase chain reaction (RT-PCR) - based tests. The Company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Companys business is its ability to provide expansive options and flexibility for all clients unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

About Picture Genetics

Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from the ease and comfort of home, at an affordable price point. The Picture Genetics platform provides a holistic approach to at-home genetic screening by including oversight from independent physicians as well as genetic counseling options to complement Fulgent Genetics comprehensive genetic testing analysis. The Picture Genetics platform currently offers multiple tests, providing medically actionable, clinical-level results with professional medical follow-up in one easy process. Visit http://www.picturegenetics.com for more information.

Investor Relations Contact:The Blueshirt GroupMelanie Solomon, 415-217-4964, melanie@blueshirtgroup.com

Read more from the original source:
Fulgent Genetics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference - GlobeNewswire

Recommendation and review posted by Bethany Smith

Global Genetic Testing Services Marketis a well-synchronized synopsis of the market, highlighting real-time research analysis that enables quick and efficient business preference. The report delivers valuable data with the aid of fragmenting the market into different segments. The report is a quick reference point which enhances reader understanding of the volatile market situations that collectively drive broad growth opportunities in the globalGenetic Testing Servicesmarket. Various vital elements are covered in the global market research report, including regional industry perspectives, geographic developments, country-level assessment, competitive environment, market share analysis of companies.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/362223/request-sample

New Industry Trends:

The analysis report focuses on development trends by regions, competitive analysis of the market as well as major drivers and restraints. The competitive analysis is given to help readers know the difference between players. The report offers an in-deep insight into the up-to-date trends of the market along with existing and upcoming opportunities for the new players in arriving globalGenetic Testing Servicesmarket. The report covers numerous key insights such as market size, products, and application along with their market share and growth rate. Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.

The report also includes information for the next five years as forested data and the past five years as past data and the market share of several key information. Major players within this globalGenetic Testing Servicesmarket are explored with their company profile, product specifications, capacity, production value, and market shares for each company. Additional details covered in this report include company description, major business, company total revenue, and the production capacity, price, revenue generated in business, product introduction, recent developments, etc.

Top key players profiled in this report:Laboratory Corporation of America Holdings, Genomic Health, Inc., NeoGenomics Laboratories, Inc., Quest Diagnostics Incorporated, Eurofins Scientific, Ambry Genetics, Hoffmann-La Roche Ltd, Illumina, Inc., CENTOGENE AG, 23andMe, Sequenom, GeneDx, Abbott, Cepheid Inc., and others.

Region Analysis: The report then estimates 2020-2025 market development trends of the globalGenetic Testing Servicesmarket. The study has added the analysis of upstream raw materials, downstream demand, and current market dynamics. Finally, the report makes some important proposals for a new project of the market before evaluating its feasibility.

Geographically regions covered in this report:North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

Request forCustomization:https://www.fiormarkets.com/enquiry/request-customization/362223

Report Highlights:

ACCESS FULL REPORT:https://www.fiormarkets.com/report/global-genetic-testing-services-market-by-test-type-362223.html

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

See the rest here:
Global Genetic Testing Services Market 2020 with Covid-19 Impact Analysis and Forecast by 2025 - Good Night, Good Hockey

Recommendation and review posted by Bethany Smith

Genetic Testing Industry Market report 2020, discourses numerous driving factors or restraining the market, which will help the future market to raise with a huge CAGR. The Genetic Testing Market research Reports offers an all-encompassing collection of reports on different markets covering essential details. The Genetic Testing Market report studies the viable environment of the Genetic Testing Market is based on company profiles and their efforts on growing product value and production.

As per the findings of the presented study, the Genetic Testing Market is poised to exceed the value of ~US$ XX by the end of 2026 emergent at a CAGR of ~XX% over the assessment period.

Request a Sample Copy to Understand the Impact of COVID-19 on Genetic Testing Market:

https://www.reportspedia.com/report/life-sciences/global-genetic-testing-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/68234#request_sample

Major Key Players:

HI GeneRegulatoryAnnoroadSinoGenoMaxGenePlanetCounsyl, Inc.RepconexNatera, IncBiomarkerGeeppine360Jiyin23andMe, IncCapitalBioBiomedlabGene by GeneUnited GeneGeneDxFind Bio-TechAiyin GeneCourtagen Life SciencesAgenGeneTestsAsper BiotechPathway GenomicsNovogeneBGIGene KangBerry GenomicsAijiyin

Geographically Regions covered in this report:

Segment by Type

CancerCystic fibrosisSickle cell anemiaDuchenne muscular dystrophyAlzheimer diseaseThalassemiaHuntington diseaseOthers

Segment by Application:

Newborn screeningDiagnostic testingCarrier testingPreimplantation genetic diagnosisPrenatal diagnosisPredictive and presymptomatic testingPharmacogenomics

Ask For Discount @:

https://www.reportspedia.com/discount_inquiry/discount/68234

The competitive analysis included in the global Genetic Testing Market study allows their readers to know the difference between players. The Genetic Testing research study gives an in-deep insight on the up-to-date trends of the market along with the opportunities for the new players in arriving global Genetic Testing Market. The readers of the Genetic Testing Market report also provide numerous key insights such as market size, Products, and application along with their market share and growth rate. The report also includes information for the next five years as forested data and the past five years as past data and the market share of several key information.

The Genetic Testing Market Report offers SWOT examination and venture return investigation, and other aspects of financial situations with benefit, generation, request, limit, supply, and market development rate and figure.

If you have any questions on this report, please reach out to us@

https://www.reportspedia.com/report/life-sciences/global-genetic-testing-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/68234#inquiry_before_buying

Genetic Testing Market Report Structure:

Report Highlights:

The report has 150 tables and figures browse the report description and TOC:

Table of Contents

1 Genetic Testing Market Study Coverage

1.1 Genetic Testing Product

1.2 Key Market Segments in This Genetic Testing Study

1.3 Key Manufacturers Covered

1.4 Genetic Testing Market by Type

1.4.1 Global Genetic Testing Market Size Growth Rate by Type

1.5 Genetic Testing Market by Application

1.5.1 Global Genetic Testing Size Growth Rate by Application

2 Executive Summary

2.1 Global Genetic Testing Market Size

2.1.1 Global Genetic Testing Revenue 2014-2026

2.1.2 Global Genetic Testing Production 2014-2026

2.2 Genetic Testing Growth Rate (CAGR) 2020-2026

2.3 Genetic Testing Market Analysis of Modest Landscape

2.3.1 Manufacturers Market Concentration Ratio

2.3.2 Key Genetic Testing Manufacturers

2.3.2.1 Genetic Testing Manufacturing Base Distribution, Headquarters

2.3.2.2 Genetic Testing Product Offered

2.3.2.3 Date of Manufacturers in Genetic Testing Market

2.4 Key Trends for Genetic Testing Markets & Products

3 Market Size by Manufacturers

3.1 Genetic Testing Production by Manufacturers

3.1.1 Genetic Testing Production by Manufacturers

3.1.2 Genetic Testing Production Market Share by Manufacturers

3.2 Genetic Testing Revenue by Manufacturers

3.2.1 Genetic Testing Revenue by Manufacturers (2020-2026)

3.2.2 Genetic Testing Revenue Share by Manufacturers (2020-2026)

3.3 Genetic Testing Price by Manufacturers

3.4 Mergers & Acquisitions, Expansion Plans

More Information.

Get a Full Table of Content:

https://www.reportspedia.com/report/life-sciences/global-genetic-testing-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/68234#table_of_contents

Continue reading here:
Global Genetic Testing Market Key Companies are studied in a Latest Report and Forecast to 2026 - Scientect

Recommendation and review posted by Bethany Smith

John Wagner was 38 when he was diagnosed with late stage colon cancer, a story that resembles the late Chadwick Boseman.

LOUISVILLE, Ky. The sudden death of actor Chadwick Boseman has everyone talking about colon cancer that ended his life at 43.

It's a reminder of the cancer risk that's rising among younger generations, even more so for Black men in this country.

This week, the American Cancer Society said it saw an 8,000% increase in traffic to its colorectal cancer symptoms page since Boseman's passing. It's a combination of colon and rectal cancers (CRC), often grouped together because they have many features in common.

"When I first figured out I had colon cancer, I was 38 years old," John Wagner said.

Wagner wasn't scheduled for a colonoscopy for another 6 years. He had no family history and considered himself a healthy guy, when he started feeling weak, having severe constipation and blood in his stool.

"He didn't smoke, or drink or do anything, and here you get this diagnosis, and you're like, wait. 'How did I get here?'" his fianc, Sharise Durrett said.

Multiple doctors sent him home without screening for cancer. At least one brushed it off as diverticulitis.

"I kept asking. They said, I was too young," said Wagner. "If it wasn't for that ER nurse, no telling what might have happened."

Durrett encouraged him to go to the ER where he received a colonoscopy. That's when they found the cancer. It had already spread to his liver.

Wagner's case is one of 145,000 new colorectal cases diagnosed in the U.S. every year. While the majority are in adults older than 50, it's the younger generation that's seen a rapid increase of cases over the last decade, and if you're Black, your risk is 20% higher than most, which increases even more for men, who are already 30% higher than women in the risk category.

The reasons are not clear, but doctors have general ideas.

"We know there are risk factors, like diet, exercise, smoking, obesity, and things like that, that play into this, but I think access plays a big part of that," Dr. Michael Driscoll, a medical oncologist, with Norton Cancer Institute said.

Insurance for most people, will only cover the costs of cancer screenings, if they're at or above the recommended age. For colon cancer, it's 45, unless you have a family history. In that case, screening should start earlier at age 40 or 10 years sooner than the age their relative was diagnosed.

"Any person with CRC under the age of 50 should also undergo genetic testing to make sure they are not dealing with a hereditary cause, such as Lynch Syndrome, which affects 1 in 279 of all races and both sexes," Dr. Whitney Jones, with the Colon Cancer Prevention Project said. "It's the most common cause of genetic colon cancer in America. Family history is critical."

"The colonoscopy is the gold standard," Dr. Driscoll said.

The problem: it's developing well before our golden years, and often times, has already spread before we start experiencing symptoms.

If this is happening to you, demand a test and nothing less.

"Colon cancer is 90 percent preventable," Dr. Driscoll said.

Still, close to 53,000 colon cancer patients will die this year. "Black Panther" star Chadwick Boseman was one of them.

"We were actually watching television together when it came on as breaking news," said Durrett. "It felt as if Chadwick was a member of our family because at that moment, John's life and Chadwick's life were parallel. There were so many similarities, it was scary."

She said the two sat in silence for the next 10 minutes. They know the numbers aren't in their favor.

People with Stage 4 Colon Cancer have less than a 10% survival rate.

"Ultimately, God has the final say," Durrett said.

But that's not stopping Wagner from trying.

"My goals are set high. I'm going to beat this. I can't let it get me down. There's no giving up," Wagner said.

In Kentucky, about 70% of people above the age of 50 get screened. It's about 68% in Indiana. Dr. Driscoll says that's not good enough.

Kentucky leads the nation in both under age 50 CRC incidence and overall CRC incidence. "But our screening rates are improving more rapidly than any state in the nation," Dr. Jones said. "Also, due to the long work of many organizations, screening rates and outcomes are equal for both blacks and whites. Our greatest disparity in outcomes is actually in Appalachia."

Kentucky state laws - by statute - in CRC screening coverage, follow the American Cancer Society guidelines, stating people with no family history of polyps or CRC can be covered for screenings at age 45. Medicaid's included.

Dr. Jones says, "on-time screening at age 45 with a colonoscopy or home stool tests (FIT or stool DNA, Cologuard) will save many lives if we can get the word out. Choice gets more people engaged in screening due to shared decision making."

Contact reporter Brooke Hasch atbhasch@whas11.com. Follow her onTwitter (@WHAS11Hasch)andFacebook.

Make it easy to keep up-to-date with more stories like this. Download the WHAS11 News app now. ForAppleorAndroidusers.

Have a news tip? Emailassign@whas11.com, visit ourFacebook pageorTwitter feed.

Here is the original post:
'I kept asking, they said I was too young' | The risks of colon cancer - FirstCoastNews.com WTLV-WJXX

Recommendation and review posted by Bethany Smith

SPRINGFIELD - Dr. Nada Kawar, who represented her native Jordan in the shot put both at the 1996 and 2000 Olympic games, had plans to be an orthopedic surgeon.

However, a rotation in obstetrics and gynecology in her third year of medical school at Washington University in St. Louis, Missouri, changed her focus to womens health. She went on to a residency in obstetrics and gynecology at University of California San Francisco Medical Center and a fellowship in gynecologic oncology and breast surgery at Brown University/Women and Infants Hospital of Rhode Island that taught her how entwined breast and gynecologic cancers can be.

Her extensive training as a gynecologic oncologist she is board certified in obstetrics and gynecology and gynecologic oncology, and certified in breast disease as well as breast surgery and in the fundamentals of laparoscopic surgery qualifies her to both diagnose as well as provide surgical and medical treatment for womens cancers, including cancers of the breast, uterus, ovaries, cervix, vagina and vulva.

Kawar, who was an undergraduate at the University of California in Los Angeles when studies were emerging on inherited risks for womens cancers and how they can overlap, now practices at Mercy Medical Centers recently opened Center for Breast Health and Gynecologic Oncology, formerly its Breast Health Center, under Dr. James Frank, and feels very lucky to have the one-stop location adjacent to the Sister Caritas Cancer Center for her patients who sometimes have overlapping cancers.

This vision of seeing everyone in the same building, sharing resources, imagining my career in a different way - I am very lucky to be here, said Kawar, noting that inherited mutations in certain genes can put a small percentage of the population at risk for breast cancer as well as ovarian cancer and cancer of the endometrium-uterus.

I have already seen lots of patients who have both cancers of the breast as well as gynecologic. Here, they can come to one space, see one doctor or other doctors and do not have to go to other locations.

She sees such an approach where a physician like herself provides comprehensive care for female cancers in one location as all about womens cancer care.

Kawar added patients at the center have access to a genetics counselor who can help determine cancer risk based on inherited factors and treatment options that range from surgery to reduce such risk to minimally invasive surgeries as well as radical procedures for those with malignancies.

She said that as medicine evolved over the last century that there was this sort of arbitrary separation of breast surgery into the field of general surgery where gynecologic oncology evolved within a subspecialty of gynecology and obstetrics.

There was this separation and finally care of breast cancers separate from gynecologic and pelvic cancers, Kawar said.

Breast cancers are mostly uniquely female, although some men get breast cancer, it is a very much a womans cancer.

The greater prevalence of breast cancer and the growing number of disease survivors, Kawar added, has helped generated much greater publicity and funding around it than cancers of the reproductive organs that are much less common though can be related.

Kawar said patients are most often referred to her by their gynecologist after an imaging study indicating a tumor or some other abnormality.

She said the most common gynecologic cancers she sees in patients are uterine cancer, which is often found early due to abnormal bleeding or pain and has a high five-year survival rate when detected in the localized state; ovarian cancer which she termed much more deadly as it is often detected when the disease is more advanced; and cervical cancer that is often caused by exposure to certain strains of the human papillomavirus and for which there is now a vaccine to help prevent.

Screening for cervical cancer can be done by the HPV or Pap test and the five-year survival rate is very high when detected at the localized stage.

Risk factors for uterine or endometrial cancer, Kawar said, include metabolic syndrome, whose conditions include high blood pressure, obesity and diabetes, but just how this syndrome contributes to the development of the cancer is unknown.

She said too much of the hormone estrogen without the presence of progesterone can also pose a risk.

Kawar said hereditary breast and ovarian cancer syndrome, often related to certain mutations in the BRCA1 or the BRCA2 gene, can elevate an individuals risk for both as well as other cancers.

She noted that there is no good screening test for ovarian cancer and one recommendation for women with a known inherited risk for the disease is risk-reducing surgery to remove the Fallopian tubes and ovaries after child bearing years.

She added, The symptoms of ovarian cancer are normally very vague - urinary symptoms like urgency or frequency, abdominal pain, feeling full quickly - these usually cause women to ultimately seek care and are often have their symptoms mistaken for stomach problems or indigestion and with a diagnosis of ovarian cancer quite late because of that.

Anyone with a strong family history of breast or ovarian cancers should seek genetic counseling and possibly genetic testing because that is one way to become aware of the risk for ovarian cancer, Kawar said.

Other risk factors include infertility - not being able to bear children - and age. It normally affects women age 60 and above.

Kawar said not all women referred to the center end up being treated for a malignant condition, but surgery is sometimes needed because of a concern for cancer.

When a woman is referred to me with a pelvic mass found on imaging, I will talk about the possibility of cancer with the goal of surgery to remove the mass and determine diagnosis and if it is cancer, to recommend the appropriate treatment which may include more extensive surgery or chemotherapy, Kawar said.

I often treat women for endometriosis which is a benign condition but can mimic cancer in the problems it causes and might require a large-scale surgical approach. I often see women for uterine bleeding that may end up being polyps and not necessarily cancer.

Kawar noted that this is Gynecological Cancer Awareness Month, and next month brings Breast Cancer Awareness Month.

September brings awareness of all the problems of the gynecologic cancers and the importance to survival of catching them early, Kawar said.

With a lot of emphasis on breast cancer in October.

The American Cancer Society estimates this year that 42,170 women will die of breast cancer, and some 33,602 will die of cancers of the genital system.

These include 13,940 of ovarian cancer, 12,590 of uterine cancer, 4,290 of cervical cancer, 1,350 of vulva cancer and 1,450 of vaginal and related cancers.

Read this article:
Mercy Medicals new Center for Breast Health, Gynecologic Oncology is all about womens cancer care - masslive.com

Recommendation and review posted by Bethany Smith